Clinical Research

United States – October 29, 2026 -- High-dose loop diuretics combined with adjuvant therapy produced an adjusted average weight loss of 4.6 pounds in heart failure inpatients, the largest of any strategy, but also came with higher rates of acute kidney injury, according to a study in the Journal of Cardiac Failure.

Study tracks 109,000 heart failure patients across US health systems

Researchers used Truveta Data to identify more than 109,000 patients hospitalized for heart failure between 2015 and 2022. Patients were grouped by the most intensive diuretic strategy used within the first 48 hours, ranging from low-dose loop diuretics alone to high-dose loop diuretics combined with thiazides or acetazolamide.

The team measured weight loss, hemoconcentration, in-hospital acute kidney injury, and the combined outcome of readmission or death within 90 days.

North Chicago – October 17, 2026 -- AbbVie (NYSE: ABBV) is presenting 20 new scientific abstracts from its inflammatory bowel disease (IBD) portfolio at the 2026 United European Gastroenterology (UEG) Week, held October 17-20 in Barcelona, Spain. The data cover long-term and real-world outcomes for Skyrizi (risankizumab) and Rinvoq (upadacitinib) in Crohn's disease (CD) and ulcerative colitis (UC).

Risankizumab maintains remission in UC through week 96

In the COMMAND study, patients on risankizumab 180 mg reached as-observed clinical remission rates of 54.0%-73.1% at week 96. Endoscopic remission rates were 38.8%-53.5%. The ranges span advanced therapy-naïve and advanced therapy-experienced patients, and the study reports up to three years of maintenance treatment.

Los Angeles – October 16, 2026 -- Fengate Private Equity, a division of Fengate Asset Management, has partnered with Clinical Research of West Florida (CRWF), an independent trial site operator with more than 1,000 completed trials, in a deal with undisclosed terms.

Westcove Partners, LLC acted as exclusive financial advisor to CRWF. Its deal team comprised Managing Directors Justin Hand and Abe M'Bodj, Director Bill Bolding, Vice President Geno Catalano and Associate Andrew Hartono.

CRWF runs three Phase I-IV facilities across Tampa Bay

Founded in 1995, CRWF operates three Phase I-IV facilities in the Tampa Bay area. The company has conducted more than 1,000 trials across a broad range of therapeutic areas and has differentiated expertise in complex autoimmune and rheumatology indications.

Bridgewater, N.J. – – October 14, 2026 -- Insmed (Nasdaq: INSM) will present four abstracts on its investigational inhaled therapy treprostinil palmitil inhalation powder (TPIP) at CHEST 2026 in Phoenix, three of them late-breaking, and two ARIKAYCE abstracts at IDWeek 2026 in Washington, D.C. CHEST runs Oct. 18–21 and IDWeek runs Oct. 21–24.

Chief Medical Officer Martina Flammer said the presentations span the company's respiratory portfolio of BRINSUPRI, TPIP and ARIKAYCE.

Philadelphia – October 13, 2026 -- Breakthrough T1D, formerly JDRF, closed its inaugural Clinical & Research Congress after more than 80 sessions and scheduled the 2027 edition for Washington, D.C., October 15-17, 2027.

The congress ran October 9-11, 2026, in Philadelphia. It brought together clinicians, researchers, scientists, healthcare professionals, industry leaders, people with lived experience and community advocates.

Sessions span immunotherapies, islet cell therapies and AI-driven tools

The program covered endocrinology, discovery science and immunotherapies, and emerging technologies including AI and digital twins. It also addressed islet cell and disease-modifying therapies, and access to care for the type 1 diabetes (T1D) community.

Los Angeles – October 13, 2026 -- TED patients with pre-existing hearing loss were more than 60% less likely to suffer a further hearing decline when teprotumumab (TEPEZZA) infusions were spaced six weeks apart instead of the standard three, according to a retrospective study presented at the ASOPRS 57th Annual Fall Scientific Symposium.

Hearing decline hit 45% of patients on the standard schedule at 24 weeks

Nine of 20 patients (45%) on the standard three-week schedule showed a clinically significant decline on formal audiometry at 24 weeks. On the six-week schedule, the rate was about one in six. Clinical significance was defined using American Speech-Language-Hearing Association (ASHA) criteria.

The symposium ran October 8-9, 2026, at the Hyatt Regency New Orleans. Shoaib Ugradar, MD, was the presenting author. The study was led by Raymond Douglas, MD, PhD.

Dublin – October 13, 2026 -- Keenova Therapeutics plc will present an exploratory analysis of the CONFIRM trial on October 12 at the American College of Gastroenterology Annual Meeting (October 9-14, 2026). The analysis covers TERLIVAZ (terlipressin) in hepatorenal syndrome-acute kidney injury (HRS-AKI) patients who are ineligible for liver transplant.

Ten-author analysis targets liver transplant-ineligible patients

The presentation is titled "Efficacy and Safety of Terlipressin in Patients With Hepatorenal Syndrome-Acute Kidney Injury Ineligible for Liver Transplant: An Exploratory Analysis of the CONFIRM Trial." Nancy Reau, MD, Associate Director of Solid Organ Transplantation and Section Chief of Hepatology at Rush University Medical Center, is the presenting author. Nine co-authors are listed, including Kavish Patidar, Kevin Regner and Nneka N. Ufere.

Portland – October 06, 2026 -- Headlands Research - Summit Portland is marking 50 years of operation in 2026, having contributed clinical research to every FDA-approved class of Alzheimer's disease medication brought to market since 1993. The site, founded in 1976, has conducted more than 500 clinical trials in partnership with pharmaceutical companies and contract research organizations (CROs).

Stockholm – October 05, 2026 -- Moberg Pharma AB (OMX: MOB) reported that its topical onychomycosis treatment MOB-015 achieved mycological cure in 74.3% of evaluable Phase 3 patients regardless of baseline antifungal susceptibility, according to new peer-reviewed data published in the Journal of Fungi.

Researchers screened 506 dermatophyte isolates for terbinafine resistance markers

The analyses draw on the company's completed North American Phase 3 trial of MOB-015, a once-daily treatment applied for 48 weeks. The work was conducted with Professor Mahmoud Ghannoum at Case Western Reserve University in Cleveland, Ohio, examining in vitro terbinafine susceptibility across the full isolate population.

Palma de Mallorca, Spain – October 02, 2026 -- Smartee Denti-Technology concluded its first large-scale academic summit held outside China on September 19, drawing nearly 300 orthodontic clinicians from 27 countries to Palma de Mallorca and unveiling two new clear-aligner product systems for international markets.

Smartee debuts SA/SA Plus and AG KIDS systems at two-day event

The Smartee European Summit 2026 served as the international launch platform for Smartee SA/SA Plus, a clear-aligner system incorporating a locking mechanism to address primary snoring and mild-to-moderate obstructive sleep apnea alongside orthodontic treatment. The company also introduced Smartee AG KIDS, a craniofacial growth guidance system for patients aged 3 to 16 that targets sagittal, vertical and transverse growth management paired with orofacial myofunctional training appliances.